Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET
Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET
Aim(s): We evaluate our experience in metastatic WD NET patients (pt) treated with Oxaliplatine based regimen (OxaliCT) and Capecitabine (Cp)
Materials and methods: From October 2005 to September 2014, 56 pretreated WD NET pt with progressive disease were treated with Cp regimen (31 pt) or OxaliCT (25 pt) (2 pt exluded for toxicity after first cicle). Pt in Cp regimen received Cp only as chemotherapy, pt in OxaliCT regimen recived capecitabine/oxaliplatin (XELOX), or leucovorin/fluorouracil/oxaliplatin (FOLFOX). The primary tumor site was pancreas, gastrointestinal tract, lung and unknown in 20, 16, 9 and 12 pt respectively. Treatment efficacy was evaluated by response rate and in terms of PFS.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Marconcini R
To read the full abstract, please log into your ENETS Member account.